B. Remmerie

发表

Comparison of Capillary and Venous Drug Concentrations After Administration of a Single Dose of Risperidone, Paliperidone, Quetiapine, Olanzapine, or Aripiprazole

B. Remmerie, M. De Meulder, S. Weiner, 2016, Clinical pharmacology in drug development.

Single‐ and Multiple‐Dose Pharmacokinetics and Dose Proportionality of the Psychotropic Agent Paliperidone Extended Release

N. Osselaer, A. Cleton, B. Remmerie, 2009, Journal of clinical pharmacology.

Validated method for the determination of risperidone and 9-hydroxyrisperidone in human plasma by liquid chromatography-tandem mass spectrometry.

N. C. van de Merbel, B. Remmerie, J. D. de Jong, 2003, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Comparison of alfentanil, fentanyl and sufentanil for total intravenous anaesthesia with propofol in patients undergoing coronary artery bypass surgery.

K. Olkkola, J. Ahonen, B. Remmerie, 2000, British journal of anaesthesia.

Comparison of Capillary and Venous Plasma Drug Concentrations After Repeated Administration of Risperidone, Paliperidone, Quetiapine, Olanzapine, or Aripiprazole

B. Remmerie, M. De Meulder, A. Savitz, 2016, Clinical pharmacology in drug development.

Translational evaluation of novel selective orexin-1 receptor antagonist JNJ-61393215 in an experimental model for panic in rodents and humans

T. P. Lebold, P. Bonaventure, W. Drevets, 2020, Translational Psychiatry.

Antiviral Activity of Oral JNJ-53718678 in Healthy Adult Volunteers Challenged With Respiratory Syncytial Virus: A Placebo-Controlled Study

D. Roymans, Young-In Kim, D. Huntjens, 2018, The Journal of infectious diseases.

Pharmacokinetics and tolerability of long-acting risperidone in schizophrenia

B. Remmerie, E. Mannaert, M. Eerdekens, 2004, Schizophrenia Research.

Rapidly disintegrating risperidone in subjects with schizophrenia or schizoaffective disorder: a summary of ten phase I clinical trials assessing taste, tablet disintegration time, bioequivalence, and tolerability.

B. Remmerie, E. Mannaert, S. Kushner, 2007, Clinical therapeutics.

Prolongation of cardiac ventricular repolarization under paliperidone: how and how much?

S. Gopal, B. Remmerie, I. Nuamah, 2012, Journal of cardiovascular pharmacology.

Pharmacokinetics and D2 receptor occupancy of long-acting injectable risperidone (Risperdal Consta) in patients with schizophrenia.

S. Nyberg, B. Eriksson, B. Remmerie, 2005, The international journal of neuropsychopharmacology.

1958. Antiviral Effects, Pharmacokinetics (PK), and Safety of the Respiratory Syncytial Virus (RSV) Fusion Protein Inhibitor, JNJ-53718678 (JNJ-8678), in RSV-infected Infants With Bronchiolitis, in the Phase 1b Study 53718678RSV1005

E. Baraldi, F. Martinón-Torres, D. Huntjens, 2018, Open Forum Infectious Diseases.

Expansion of guidance for the day 8 initiation dose of paliperidone palmitate to avoid a missed dose

L. Alphs, S. Gopal, B. Remmerie, 2013, Neuropsychiatric disease and treatment.

Population Pharmacokinetics of Paliperidone Palmitate (Once‐Monthly Formulation) in Japanese, Korean, and Taiwanese Patients With Schizophrenia

Y. Tsukamoto, S. Gopal, B. Remmerie, 2019, Clinical pharmacology in drug development.

Pharmacokinetics, safety, and tolerability of paliperidone palmitate 3‐month formulation in patients with schizophrenia: A phase‐1, single‐dose, randomized, open‐label study

S. Gopal, B. Remmerie, M. De Meulder, 2016, Journal of clinical pharmacology.

Pharmacokinetic comparison of fast-disintegrating and conventional tablet formulations of risperidone in healthy volunteers.

P. Lechat, K. Lasseter, B. Remmerie, 2003, Clinical therapeutics.

Integrating Duodenal Sampling in a Human Mass Balance Study to Quantify the Elimination Pathways of JNJ-53718678, a Respiratory Syncytial Virus Fusion Protein Inhibitor

D. Huntjens, B. Remmerie, M. De Meulder, 2019, Advances in Therapy.

Pharmacokinetics, Safety, and Antiviral Effects of Multiple Doses of the Respiratory Syncytial Virus (RSV) Fusion Protein Inhibitor, JNJ-53718678, in Infants Hospitalized With RSV Infection: A Randomized Phase 1b Study

E. Baraldi, F. Martinón-Torres, D. Huntjens, 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

A comparison of serum prolactin concentrations after administration of paliperidone extended-release and risperidone tablets in patients with schizophrenia

A. Cleton, B. Remmerie, L. Janssens, 2010, Journal of psychopharmacology.

Validated LC-MS/MS methods for the determination of risperidone and the enantiomers of 9-hydroxyrisperidone in human plasma and urine.

N. C. van de Merbel, P. Timmerman, B. Remmerie, 2008, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Absorption, Metabolism, and Excretion of Paliperidone, a New Monoaminergic Antagonist, in Humans

A. Cleton, B. Remmerie, G. Mannens, 2008, Drug Metabolism and Disposition.

Pharmacokinetic profile of long-acting injectable risperidone at steady-state: comparison with oral administration.

J. Levron, B. Remmerie, A. Vermeulen, 2005, L'Encephale.

Effect of carbamazepine on the pharmacokinetics of paliperidone extended‐release tablets at steady‐state

A. Cleton, B. Remmerie, A. Vandebosch, 2014, Clinical pharmacology in drug development.

Plasma pharmacokinetic characteristics of risperidone and their relationship to saliva concentrations in children with psychiatric or neurodevelopmental disorders.

A. Vinks, M. Aman, Yaser Ramadan, 2007, Clinical therapeutics.

A Receiver Operating Characteristic Framework for Non-adherence Detection Using Drug Concentration Thresholds—Application to Simulated Risperidone Data in Schizophrenic Patients

J. Pérez-Ruixo, B. Remmerie, A. Vermeulen, 2019, The AAPS Journal.

Efficacy and Safety of the 3-Month Formulation of Paliperidone Palmitate vs Placebo for Relapse Prevention of Schizophrenia: A Randomized Clinical Trial.

Yanning Liu, S. Gopal, B. Remmerie, 2015, JAMA psychiatry.

A randomized trial of paliperidone palmitate and risperidone long-acting injectable in schizophrenia.

W. Fleischhacker, S. Gopal, P. Lim, 2012, The international journal of neuropsychopharmacology.

Pharmacokinetic profile after multiple deltoid or gluteal intramuscular injections of paliperidone palmitate in patients with schizophrenia

A. Cleton, H. Crauwels, B. Remmerie, 2015, Clinical pharmacology in drug development.

Management of antipsychotic treatment discontinuation and interruptions using model-based simulations

L. Alphs, J. Sheehan, B. Remmerie, 2012, Clinical pharmacology : advances and applications.

Efficacy and safety of paliperidone palmitate in adult patients with acutely symptomatic schizophrenia: a randomized, double-blind, placebo-controlled, dose-response study

S. Gopal, B. Remmerie, C. Gassmann-Mayer, 2010, International clinical psychopharmacology.

A single‐dose, open‐label, parallel, randomized, dose‐proportionality study of paliperidone after intramuscular injections of paliperidone palmitate in the deltoid or gluteal muscle in patients with schizophrenia

S. Gopal, A. Cleton, H. Crauwels, 2014, Journal of clinical pharmacology.

A double-blind study of paliperidone palmitate and risperidone long-acting injectable in adults with schizophrenia

S. Gopal, B. Remmerie, G. Pandina, 2011, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

A one-year prospective study of the safety, tolerability and pharmacokinetics of the highest available dose of paliperidone palmitate in patients with schizophrenia

Yanning Liu, S. Gopal, B. Remmerie, 2012, BMC Psychiatry.

Pharmacokinetics and safety of combination therapy with lithium and risperidone.

W. Sperling, B. Remmerie, E. Mannaert, 2006, Pharmacopsychiatry.

Paliperidone extended-release as adjunctive therapy to lithium or valproate in the treatment of acute mania: a randomized, placebo-controlled study.

P. Lim, B. Remmerie, I. Nuamah, 2011, Journal of affective disorders.

A Post-hoc comparison of paliperidone palmitate to oral risperidone during initiation of long-acting risperidone injection in patients with acute schizophrenia.

S. Gopal, B. Remmerie, G. Pandina, 2011, Innovations in clinical neuroscience.

Drug‐Drug Interaction Studies of Paliperidone and Divalproex Sodium Extended‐Release Tablets in Healthy Participants and Patients with Psychiatric Disorders

B. Remmerie, M. Meulder, J. Berwaerts, 2016, Journal of clinical pharmacology.

Determination of plasma concentration reference ranges for oral aripiprazole, olanzapine, and quetiapine

B. Remmerie, A. Vermeulen, B. Green, 2018, European Journal of Clinical Pharmacology.

Effect of carbamazepine on the pharmacokinetics of paliperidone extended‐release tablets at steady‐state

A. Cleton, B. Remmerie, A. Vandebosch, 2014, Clinical pharmacology in drug development.

Paliperidone extended-release as adjunctive therapy to lithium or valproate in the treatment of acute mania: a randomized, placebo-controlled study.

P. Lim, B. Remmerie, I. Nuamah, 2011, Journal of affective disorders.